J Gynecol Oncol.
2019 Sep;30(5):e86. 10.3802/jgo.2019.30.e86.
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
- Kok PS
- Beale P
- O'Connell
- Grant P
- Bonaventura T
- Scurry J
- Antill Y
- Goh J
- Sjoquist K
- DeFazio A
- Mapagu C
- Amant F
- Friedlander M
- on behalf of the PARAGON Investigators
- Affiliations
-
- 1National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia. Peey-sei.kok@ctc.usyd.edu.au
- 2Chris O'Brien Lifehouse, Sydney, NSW, Australia.
- 3Mercy Hospital for Women, Melbourne, VIC, Australia.
- 4Calvary Mater Newcastle, Newcastle, NSW, Australia.
- 5Peninsula Health, Frankston, VIC, Australia.
- 6Royal Brisbane and Women's Hospital, Brisbane & University of Queensland, St Lucia, QLD, Australia.
- 7School of Medicine, University of Queensland, Brisbane, QLD, Australia.
- 8Cancer Care Centre St George Hospital, Sydney, NSW, Australia.
- 9The Westmead Institute for Medical Research, Sydney, NSW, Australia.
- 10University of Sydney, Sydney, NSW, Australia.
- 11Westmead Hospital, Sydney, NSW, Australia.
- 12Department of Gynecologic Oncology, UZ Gasthuisberg KU Leuven, Leuven, Belgium.
- 13Prince of Wales Hospital and Royal Hospital for Women, Sydney, NSW, Australia.
- KMID: 2457159
- DOI: http://doi.org/10.3802/jgo.2019.30.e86
Abstract
OBJECTIVE
A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity of anastrozole in patients with ER+ and/or progesterone receptor (PR)-positive (PR+) recurrent/metastatic gynecological cancers.
METHODS
Postmenopausal women with ER+ and/or PR+ ROC, who were asymptomatic and had cancer antigen 125 (CA125) progression after response to first line chemotherapy, where chemotherapy was not clinically indicated. Patients received anastrozole 1 mg daily until progression or unacceptable toxicity.
RESULTS
Fifty-four patients were enrolled (52 evaluable). Clinical benefit at three months (primary endpoint) was observed in 18 patients (34.6%; 95% confidence interval [CI]=23%-48%). Median progression-free survival (PFS) was 2.7 months (95% CI=2.1-3.1). The median duration of clinical benefit was 6.5 months (95% CI=2.8-11.7). Most patients progressed within 6 months of starting anastrozole but 12 (22%) continued treatment for longer than 6 months. Anastrozole was well tolerated. In the exploratory analysis, ER histoscores and the intensity of ER staining did not correlate with clinical benefit rate or PFS.
CONCLUSION
A subset of asymptomatic patients with ER+ and/or PR+ ROC and CA125 progression had durable clinical benefit on anastrozole, with acceptable toxicity. Anastrozole may delay symptomatic progression and the time to subsequent chemotherapy. The future challenge is to identify the subset of patients most likely to benefit from an aromatase inhibitor and whether the clinical benefit could be increased by the addition of other agents.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Estrogen and Progesterone Receptor-Positive Male Breast Cancer
- A Case of Estrogen Dermatitis
- The Estrogen and Progesterone Receptor Expressions in Thyroid Nodules
- Study for estrogen receptor and progesterone receptor of colorectal carcinoma
- Treatment Outcomes of Weakly Positive Hormone Receptor Breast Cancer and Triple-Negative Breast Cancer
